United States: New York Attorney General Enters Digital Health App And Privacy Enforcement Fray: Announces Three Settlements With Health And Fitness App Providers' Due To Efficacy Claims And Privacy Practices

Last Updated: April 12 2017
Article by James S. DeGraw

On March 23, the New York Office of the Attorney General ("NY OAG") announced Assurances of Discontinuance ("Settlements") with three developers of health and fitness mobile apps. The Settlements appear to mark the NY OAG's first endeavor into investigating the efficacy claims and privacy practices of these types of apps. The Settlements are notable for, among other things, including requirements that the app providers (i) clearly state that their apps are not for medical use; (ii) cease collecting certain user information, such as device identifiers; (iii) obtain affirmative consent from users to collect and share other sensitive information; (iv) inform users that data collected by an app may not be protected under the Health Insurance Portability and Accountability Act ("HIPAA"); and (v) inform users that aggregated app data that does not identify users personally may be shared with third parties and that those third parties might be able to reidentify specific users.

The Heart & Fetal Heart Monitoring Apps

Two of the apps, known as Cardiio (provided by Cardiio, Inc.) and Runtastic (provided by Runtastic GmbH), were promoted as helping consumers monitor their heart rate using a phone's camera. Those apps were available in the Health & Fitness section of app stores, for free or a small fee, where the providers claimed the apps could turn an iPhone into a personal heart rate monitor. Both claimed that their app could accurately capture a person's heart rate, even after exercise. Cardiio also claimed it could estimate one's life expectancy using the data the app collected.

Neither Cardiio nor Runtastic required users to expressly consent to the app's data collection practices, appearing to rely on notice through making a privacy policy available and implied consent. Among other things, the Cardiio app could collect GPS information and Runtastic unique device identifiers. Neither expressly disclosed that fact. Runtastic also had a live tracking feature that could share your location with third parties.

The third app, known as My Baby's Beat-Baby Heart Monitor App, was provided by Matis Ltd. The app was the most popular paid app in the Apple App Store medical category in 2016, and had as its logo a baby inside a stethoscope. Using only a phone's microphone, Matis claimed in the Apple App Store that "you can listen to your baby's heartbeat and movements, just like a Fetal Heart Monitor." In the Google Play store, Matis claimed that "[i]nstead of buying a home Doppler you can turn your smartphone in a Fetal heart monitor, using ONLY the PHONE'S MICROPHONE and a pair of headphones."

The data the app collected included global unique device identifiers, user feedback, an engagement score, and recordings. Though a privacy policy was available to users of the My Baby's Beat app, the policy did not disclose that that information was collected. The policy did disclose that data might be shared on an aggregated basis, but did not disclose risks associated with that practice.

In pursuing these investigations and settlements, the NY OAG relied on NY statutes prohibiting "deceptive acts or practices in the conduct of business" and "false advertising in the conduct of any business." N.Y. Gen. Bus. Law §§ 349, 350. While the targets neither admitted nor denied the NY OAG finding, the NY OAG Settlement with each is premised on the NY OAG's claims that "[m]arketing a Health Measurement App without substantiation that it accurately measures what it purports to measure, and without fully and clearly disclosing privacy practices, constitute deceptive trade practices." The NY OAG's allegations regarding both parts of this allegation are noteworthy. The first part – regarding claims of what the app can accomplish – stands as a warning itself for all providers of Life Style or Health & Fitness apps to ensure claims indeed are accurate. The second part – regarding data collection practices – if continued to be pressed by the New York and OAG, could result in a significant change in app data collection and sharing practices.

The Advertising Claims

With respect to the app providers' claims, the NY OAG in each Settlement noted that heart and fetal heart rate monitors generally are regulated as Class II medical devices by the FDA. Class II devices are higher risk devices than Class I devices, and "require greater regulatory controls to provide reasonable assurance of the device's safety and effectiveness."

The NY OAG alleged that claims made by Cardiio and Runtastic conveyed a "net impression" that the applications could accurately measure and monitor heart rates of users engaged in vigorous exercise – akin to heart rate monitors. But the applications did not provide sufficient evidence to substantiate such claims. In fact, it was not clear that the applications had been tested on users engaged in vigorous exercise.

As for the My Baby's Beat app, the NY OAG alleged that Matis informed users they could use My Baby's Beat instead a fetal heart monitor or Doppler device. This claim was made despite the absence of FDA approval or clearance, and despite Matis not having conducted testing to compare its application to fetal heart monitors or Doppler devices. The New York OAG found all three apps could potentially harm consumers by providing inaccurate or misleading results.

In the Settlements, each of the app providers agreed to provide clear and prominent warnings. Matis revised its descriptions on app stores to state that My Baby's Beat app is not to be used for medical decisions of any kind. The providers of the heart monitor apps added warnings that those apps are not for medical use, and not cleared or approved by the FDA. As for the fetal heart monitor app, the provider also changed the name and logo of the app, and agreed to move the app from the "Medical" to "Lifestyle" app category.

The Privacy Claims

All three apps had privacy policies that appeared to rely on consumer consent by default. The Settlements state that the heart rate monitor app providers "maintain[ed]" privacy policies while the fetal heart monitor app providers made a privacy policy "available" to users. None appear to have required express user consent.

The NY OAG also found individual data handling and disclosure practices by the app providers troubling under New York's consumer deception laws. Cardiio, for instance:

  1. could collect GPS location "which, when combined with other information about a user, may be personally identifiable information";
  2. could disclose aggregated data to third parties, but failed to disclose "the risk that third parties who receive such data . . . may reidentify specific users"; and
  3. did not disclose that "personal health information" (such as heart-related conditions) collected, stored and shared by Cardiio "may not be protected under the Health Insurance Portability and Accountability Act ('HIPAA')."

The Runtastic and Matis apps collected device identification information, which the New York OAG termed "personally identifiable information" in those Settlements.

In support of its claims that the risk of reidentification of aggregated data should be disclosed, the NY OAG in each Settlement cites papers by Prof. Paul Ohm and Prof. Latanya Sweeney that cast doubt on the efficacy of anonymization techniques, especially among combined data sets. See Paul Ohm, Broken Promises of Privacy: Responding to the Surprising Failure of Anonymization, 57 UCLA L. Rev. 1701 (2010); Latanya Sweeney, Only You, Your Doctor, and Many Others Know, Technology Sci. (2015).

The NY OAG also criticized a statement in the Cardiio privacy policy that it could disclose user information to third parties if it believed in good faith that disclosure was "reasonably necessary to protect the property or rights of Cardiio, third parties or the public at large." The Cardiio Settlement states that "[t]his conferred virtually unlimited discretion on Cardiio, Inc. in disclosing users' personal information."

In the Settlements, the heart monitor app providers agreed to obtain express consent to their data handling practices from users. This includes requiring a user to scroll through the policy and affirmatively click on a consent button. The Cardiio policy going forward needs to, among other things, clearly and prominently disclose the above risks. Runtastic made similar commitments, as well as agreeing to adopt a right-to-be-forgotten mechanism. Matis, the fetal heart monitor app provider, among other things, agreed to stop collecting user device ids.


The NY OAG's actions exemplify the increased enforcement risk for app providers from state attorneys general and other non-federal regulatory actors. With respect to health-related mobile apps, the NY OAG estimates there are more than 165,000 such apps available for download on smartphone devices. Many of these app providers are not covered by HIPAA and may presume (often incorrectly) that they are immune from FDA or state enforcement.

While the Federal Trade Commission ("FTC") has also shown interest in regulating this space, these recent NY OAG Settlements may represent a shift from federal agencies to state attorneys general in the regulation of claims and data handling procedures made by health-related apps. Although questions remain concerning the FTC's ability to regulate privacy practices under Section 5 of the Federal Trade Commission Act, the NY Attorney General, Eric T. Schneiderman, stated in announcing the Settlements that his office would "not hesitate to take action against developers that disseminate unfounded information that is both deceptive and potentially harmful to every day consumers."

Going forward, mobile app and software developers should evaluate how individual states could monitor their claims and privacy practices in addition, or in lieu of, federal regulators. Companies operating in health-related fields especially should review the claims they disseminate and the way they engage with consumer privacy data in light of the ever-developing regulatory environment.


In re: Cardiio, Inc., Assurance No.: 16-173

In re: Matis Ltd., Assurance No.: 16-101

In re: Runtastic GmbH, Assurance No.: 16-174

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions